Key Takeaways GSK said bepirovirsen met primary endpoints in two phase III studies in chronic hepatitis B patients.GSK reported a statistically significant functional cure versus SoC in patients with lower baseline HBsAg.GSK plans global regulatory filings in early 2026, positioning bepirovirsen as a finite six-month CHB therapy.GSK plc (GSK) announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational chronic hepatitis B (CHB) therapy called bepirovirsen ...